| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/29/2013 | US8361958 Oximyl HCV serine protease inhibitors |
| 01/29/2013 | US8361957 Isolated GDF trap polypeptide |
| 01/29/2013 | US8361956 Recombinant APases nucleic acid sequences |
| 01/29/2013 | US8361955 Methods for treating and preventing brain tumors based on bone morphogenetic proteins |
| 01/29/2013 | US8361795 Hepatopoietin and use thereof |
| 01/29/2013 | US8361787 Method for expression of small RNA molecules within a cell |
| 01/29/2013 | US8361772 Specific lysis of staphylococcal pathogens by bacteriophage phi11 endolysin |
| 01/29/2013 | US8361749 Process for preparing variant of Erysipelothrix rhusiopathiae surface protective antigen in E. coli |
| 01/29/2013 | US8361745 Human growth and differentiation factor GDF-5 |
| 01/29/2013 | US8361740 Peptide standards |
| 01/29/2013 | US8361733 Methods of identifying modulators of a cold-and-menthol-sensitive receptor (CMR1) and recombinant cells for use thereof |
| 01/29/2013 | US8361617 Silk fibroin materials and use thereof |
| 01/29/2013 | US8361512 Nutrient compositions and methods for enhanced effectiveness of the immune system |
| 01/29/2013 | US8361510 Nanogels for cellular delivery of therapeutics |
| 01/29/2013 | US8361485 Conditioned cell culture medium compositions and methods of use |
| 01/29/2013 | US8361479 Promiscuous PAP CD4 T cell epitopes |
| 01/29/2013 | US8361476 With a carrier peptide adjuvant that is able to strongly enhance the immune response to a specific co-administered antigen |
| 01/29/2013 | US8361471 Immunostimulatory regimen comprising administering type 1 interferon and agonistic anti-CD40 antibody |
| 01/29/2013 | US8361467 Antagonist is selected from an antioxidant or an inhibitor of a pro-inflammatory interleukin, TNF- alpha synthesis, membrane-bound TNF- alpha, a natural receptor of TNF- alpha, nitric oxide synthase, phospholipase A2, apoptosis, matrix metalloproteases, or p38 kinase |
| 01/29/2013 | US8361466 Tweak receptor |
| 01/29/2013 | US8361463 Humanized antibodies against human interferon-alpha |
| 01/29/2013 | US8361458 Method and filamentous phage for treating inflammation associated with amyloid deposits and brain inflammation involving activated microglia |
| 01/29/2013 | US8361457 Duplexed parvovirus vectors |
| 01/29/2013 | US8361456 Method of inducing differentiation of bone marrow stromal cells to neural precursor cells, neural precursor cells, and uses thereof |
| 01/29/2013 | US8361443 Peptide-based compounds |
| 01/29/2013 | US8361022 Apparatus for transdermal delivery of parathyroid hormone agents |
| 01/29/2013 | CA2591581C Gel composition and methods |
| 01/29/2013 | CA2584643C New, topically applicable actives against mimic and age-related wrinkles |
| 01/29/2013 | CA2551039C Analogues of glp-1 |
| 01/29/2013 | CA2469310C Plasmid mediated supplementation for treating chronically ill subjects |
| 01/29/2013 | CA2459822C Treatment of chronic myelogenous leukemia, resistant or intolerant to sti571, involving homoharringtonine alone or combined with other agents |
| 01/29/2013 | CA2454050C Pharmaceutical formulae for thyroid hormones and procedures for obtaining them |
| 01/29/2013 | CA2431891C Mutations in neuronal gene sodium-channel alpha 1-subunit and their polypeptides and their treatment of generalised epilepsy with febrile seizures plus |
| 01/29/2013 | CA2343929C Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| 01/29/2013 | CA2331890C Method and medium for in vitro culture of human embryos |
| 01/29/2013 | CA2322160C Vaccines, immunotherapeutics and methods for using the same |
| 01/24/2013 | WO2013013187A1 Apolipoprotein e polypeptides and their use |
| 01/24/2013 | WO2013013165A2 Use of lna compounds for therapeutic inhibition of mir-21 in systemic lupus erythematosus |
| 01/24/2013 | WO2013013105A2 Compositions and methods for re-programming cells without genetic modification for repairing cartilage damage |
| 01/24/2013 | WO2013013085A2 Anti-fibrotic peptides and their use in methods for treating diseases and disorders characterized by fibrosis |
| 01/24/2013 | WO2013013062A1 Methods of decreasing glycosylated hemoglobin in patents with dyslipidemia |
| 01/24/2013 | WO2013013056A1 Method for treating amyloid disease |
| 01/24/2013 | WO2013013042A1 Botulinum toxins for use in a method for treatment of adipose deposits |
| 01/24/2013 | WO2013012954A2 Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
| 01/24/2013 | WO2013012945A1 Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy |
| 01/24/2013 | WO2013012922A1 Adenovirus e1a fragments for use in anti-cancer therapies |
| 01/24/2013 | WO2013012921A2 Nucleic acid aptamers |
| 01/24/2013 | WO2013012811A2 Immunotherapeutic modulation of amyloidogenic disease using non-fibrillogenic, non-amyloidogenic polymerized proteins and peptides |
| 01/24/2013 | WO2013012324A1 Use of a nucleotide for improving the heat stability of an aqueous micellar casein composition |
| 01/24/2013 | WO2013012313A1 Use of a nucleotide for improving the heat stability of an aqueous micellar casein composition |
| 01/24/2013 | WO2013012138A1 Lesion-marking receptor, and drug transporter for the treatment of a lesion-related ailment |
| 01/24/2013 | WO2013012101A1 Fatty acid tripeptide salt and antibacterial composition containing same |
| 01/24/2013 | WO2013011514A1 Proteolytic extract from bromelain for the treatment of connective tissue disorders |
| 01/24/2013 | WO2013011019A1 Pharmaceutical composition for treating a respiratory disease |
| 01/24/2013 | WO2013010998A2 Compositions and methods for immunomodulation |
| 01/24/2013 | WO2013010780A1 Pharmaceutical composition for treating a metabolic syndrome |
| 01/24/2013 | WO2013010749A1 Sequential anti - ctla4 and targeted il-2 therapy |
| 01/24/2013 | WO2013010660A1 Enzymes having alpha2,9 endosialidase activity |
| 01/24/2013 | WO2013010274A1 Methods for diagnosing and treating alzheimer's disease by administering an ανίίangiogenic agent |
| 01/24/2013 | WO2013010241A1 Pharmaceutical composition for the treatment of arterial hypertension, based on the co-administration of anti-hypertensive agents and angiotensin (1-7) or another mas receptor agonist |
| 01/24/2013 | WO2013010225A1 Enzymes for degrading organophosphates |
| 01/24/2013 | WO2012166875A9 Modulating innate immune cell activity by lunasin and selected cytokines |
| 01/24/2013 | WO2012131680A3 Compositions and methods for treating inflammation based on inhibiting cd151 activity |
| 01/24/2013 | WO2007000584A8 Treatment of fungal and/or protist infections |
| 01/24/2013 | US20130024986 Transgenic plants with controlled distribution of a trait to progeny |
| 01/24/2013 | US20130023879 Method for augmenting, reducing, and repairing bone with thermoplastic materials (as amended) |
| 01/24/2013 | US20130023714 Medical and Imaging Nanoclusters |
| 01/24/2013 | US20130023647 Modified human thymic stromal lymphopoietin |
| 01/24/2013 | US20130023561 Facially Amphiphilic Polymers and Oligomers and Uses Thereof |
| 01/24/2013 | US20130023485 Parenteral formulations of peptides for the treatment of systematic lupus erythematosus |
| 01/24/2013 | US20130023484 Peripherin-specific autoantibodies as a marker for neurological and endocrinological disease |
| 01/24/2013 | US20130023483 Template-fixed peptidomimetics with cxcr7 modulating activity |
| 01/24/2013 | US20130023482 Crystalline form of cyclosporine a, methods of preparation, and methods for use thereof |
| 01/24/2013 | US20130023481 Adenovirus E1A Fragments for Use in Anti-Cancer Therapies |
| 01/24/2013 | US20130023480 Purified Bowman-Birk Protease Inhibitor Proteins Isolated from a Soy Processing Sttream |
| 01/24/2013 | US20130023479 Use of nucleolin as a biomarker for lymphangiogenesis in cancer prognosis and therapy |
| 01/24/2013 | US20130023478 Aquaretic and natriuretic polypeptides lacking vasodilatory activity |
| 01/24/2013 | US20130023477 Growth hormone fusion proteins |
| 01/24/2013 | US20130023476 Pharmaceutical Preparation Comprising Recombinant HCG |
| 01/24/2013 | US20130023475 C-met receptor regulation by angiotensin iv (at4) receptor ligands |
| 01/24/2013 | US20130023474 Compositions, uses and methods for treatment of metabolic disorders and diseases |
| 01/24/2013 | US20130023473 Methods and pharmaceutical composition for the preservation of vascular endothelial cell barrier integrity |
| 01/24/2013 | US20130023472 Ldl quantitation and method of use |
| 01/24/2013 | US20130023471 Methods to restore glycemic control |
| 01/24/2013 | US20130023470 Exendin and exendin agonists for eating disorders |
| 01/24/2013 | US20130023469 Leptin for use in increasing liver regeneration |
| 01/24/2013 | US20130023468 Liquid enteral nutritional composition suitable for tube feeding, minimizing lower and upper tract digestive conditions |
| 01/24/2013 | US20130023467 Pharmaceutical combination for use in inducing weight loss in diabetes type 2 patients or/and for preventing weight gain in diabetes type 2 patients |
| 01/24/2013 | US20130023466 Peptide YY and Peptide YY Agonists for Treatment of Metabolic Disorders |
| 01/24/2013 | US20130023465 Use of Human Chorionic Gonadotropin (hCG) by Oral-Sublingual or Injectable Route as an Appetite-Suppressant Agent. |
| 01/24/2013 | US20130023464 Novel compounds and their effects on feeding behaviour |
| 01/24/2013 | US20130023463 Hiv protease inhibiting compounds |
| 01/24/2013 | US20130023462 Lyophilized anti-fungal compositions |
| 01/24/2013 | US20130023461 Oligopeptide compounds and uses thereof |
| 01/24/2013 | US20130023460 Amphiphilic linear peptide/peptoid and hydrogel comprising the same |
| 01/24/2013 | US20130023459 Method for Preparing a Protein Emulsion |
| 01/24/2013 | US20130022685 Topical Compositions and Methods of Detection and Treatment |
| 01/24/2013 | US20130022671 Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor |
| 01/24/2013 | US20130022661 Bio-remodable bone augmentation device and method |
| 01/24/2013 | US20130022660 Drug delivery system for the prevention of cerebral vasospasm |